<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03916497</url>
  </required_header>
  <id_info>
    <org_study_id>38RC19.002</org_study_id>
    <secondary_id>2019-A00101-56</secondary_id>
    <nct_id>NCT03916497</nct_id>
  </id_info>
  <brief_title>Anti-CMV Cellular Immunity Quantification Using an IGRA Test in Kidney Transplant récipients and Hemodialysis Patients, Comparison to Control Patients</brief_title>
  <acronym>Quantiferon</acronym>
  <official_title>Quantification de l'immunité T Anti-CMV à l'Aide d'un Test IGRA Chez Des Patients greffés rénaux et Des Patients dialysés, Comparaison Avec Une Population de témoins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of anti-CMV T cellular immunity using an IGRA test (Quantiferon-CMV test) in
      kidney transplant recipients and hemodialysis patients, comparison to control patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cytomegalovirus (CMV) infection is a common opportunistic complication after kidney
      transplantation (KT). It has been associated with high morbidity and mortality in kidney
      transplant recipients (KTR). Its actual management is only based on the humoral immunity :
      the main risk factor for CMV infection after KT is the association of a seropositive donor
      and a seronegative recipient (so-called &quot;D+/R- mismatch&quot;).

      However several studies have highlighted the essential role of cellular immunity to control
      CMV infection. The Quantiferon-CMV (QF-CMV) is an IGRA test (Interferon Gamma Releasing
      Assay) which evaluates T CD8 lymphocytes production of Interferon Gamma (IFNy) exposed to CMV
      antigens. Some studies have shown the possible interest of the QF-CMV in predicting CMV
      infection after antiviral prophylaxis discontinuation or when CMV viremia is detected.

      However some limits have been underlined. First its positivity threshold hasn't been approved
      in KTR. Hemodialysis patients (HP) called to receive a renal allograft also suffered from
      altered immunity. No study has directly compared the QF-CMV value in KTR, HP and control
      patients.

      That's why we propose evaluating the expression of basal cellular immunity against CMV (far
      from any active infection) in KTR and HP using the QF-CMV and comparing it to control
      patients population (not suffering from kidney dysfunction or immunosuppression).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2019</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of anti-CMV T cellular immunity in kidney transplant recipients, hemodialysis patients and control patients.</measure>
    <time_frame>Single measurement at Day 0 of patient inclusion</time_frame>
    <description>Quantification of IFNy level producted by T cells exposed to CMV antigens using a Quantiferon-CMV test in kidney transplant recipients, hemodialysis patients and control patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of patient cellular immunity.</measure>
    <time_frame>Single measurement at Day 0 of patient inclusion</time_frame>
    <description>Quantification of lymphocytes subpopulations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of kidney transplant recipient exposure to immunosuppressive therapy.</measure>
    <time_frame>Single collection at Day 0 of patient inclusion</time_frame>
    <description>Assessment of last tacrolimus trough concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of renal function.</measure>
    <time_frame>Single measurement at Day 0 of patient inclusion</time_frame>
    <description>Evaluation of estimated glomerular filtration rate by plasmatic creatinin dosage using CKD-EPI estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of CMV donor humoral immunity in kidney transplant recipients.</measure>
    <time_frame>Single collection at Day 0 of patient inclusion</time_frame>
    <description>Assessment of donor CMV serology.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Quantiferon-CMV</condition>
  <condition>Cytomegalovirus Infections</condition>
  <condition>Kidney Transplant Infection</condition>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Group 1 : kidney transplant recipients (KTR)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 : hemodialysis patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 : Control patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Quantiferon CMV</intervention_name>
    <description>Evaluate and compare interferon gamma (IFNy) production by T CD8 cells exposed to CMV antigens in CMV seropositive kidney transplant recipients, hemodialysis and control patients</description>
    <arm_group_label>Group 1 : kidney transplant recipients (KTR)</arm_group_label>
    <arm_group_label>Group 2 : hemodialysis patients</arm_group_label>
    <arm_group_label>Group 3 : Control patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Kidney transplant recipients will be recruited among KTR followed in the Kidney transplant
        department of Grenoble University Hospital.

        Hemodialysis patients will be recruited among hemodialysis patients on the waiting list for
        a kidney transplant in the Kidney transplant department of Grenoble University Hospital.

        Control patients will be recruited among non-hemodialysis and non-kidney transplanted
        patients followed in the Grenoble University Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  For all patients :

               -  to be seropositive for CMV

               -  to not be opposed to the study

          -  For kidney transplant recipients :

               -  to have received a kidney graft for over 1 year

               -  to have received an induction therapy at transplantation time by anti-lymphocytes
                  antibodies and steroids

               -  to be currently receiving immunosuppressive therapy by calcineurins inhibitors
                  (tacrolimus or cyclosporine), mycophenolic acid with or without steroids

               -  to not suffer from another cause of immunosuppression

          -  For hemodialysis patients :

               -  to be treated by hemodialysis for end stage renal disease

               -  without prior solid organ transplant history

               -  to not suffer from another cause of immunosuppression

          -  For control patients :

               -  with normal kidney function (estimated GFR &gt; 90 ml/min)

               -  to not suffer from another cause of immunosuppression

        Exclusion Criteria :

          -  patient under guardianship or deprived of his liberty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lionel Rostaing</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Grenoble-Alpes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lionel Rostaing</last_name>
    <phone>+33 04.76.76.54.60</phone>
    <email>lrostaing@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louis Manière</last_name>
    <phone>+33 04.76.76.88.53</phone>
    <email>lmaniere@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Maniere</last_name>
      <phone>(0)4 76 76 88 53</phone>
      <phone_ext>+33</phone_ext>
      <email>lmaniere@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Johan NOBLE</last_name>
      <phone>(0)4 76 76 54 60</phone>
      <phone_ext>+33</phone_ext>
      <email>jnoble@chu-grenoble.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Radha R, Jordan S, Puliyanda D, Bunnapradist S, Petrosyan A, Amet N, Toyoda M. Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant. 2005 Jan;5(1):110-7.</citation>
    <PMID>15636618</PMID>
  </reference>
  <reference>
    <citation>Lisboa LF, Kumar D, Wilson LE, Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation. 2012 Jan 27;93(2):195-200. doi: 10.1097/TP.0b013e31823c1cd4.</citation>
    <PMID>22179399</PMID>
  </reference>
  <reference>
    <citation>Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, Venkataraman S, Humar A. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant. 2009 May;9(5):1214-22. doi: 10.1111/j.1600-6143.2009.02618.x.</citation>
    <PMID>19422346</PMID>
  </reference>
  <reference>
    <citation>Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, Kalpoe J, Lisboa L, Ely L, Kaul DR, Schwartz BS, Morris MI, Ison MG, Yen-Lieberman B, Sebastian A, Assi M, Humar A. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013 Mar;56(6):817-24. doi: 10.1093/cid/cis993. Epub 2012 Nov 29.</citation>
    <PMID>23196955</PMID>
  </reference>
  <reference>
    <citation>Cantisán S, Lara R, Montejo M, Redel J, Rodríguez-Benot A, Gutiérrez-Aroca J, González-Padilla M, Bueno L, Rivero A, Solana R, Torre-Cisneros J. Pretransplant interferon-γ secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant. 2013 Mar;13(3):738-45. doi: 10.1111/ajt.12049. Epub 2013 Jan 11.</citation>
    <PMID>23311355</PMID>
  </reference>
  <reference>
    <citation>Walker S, Fazou C, Crough T, Holdsworth R, Kiely P, Veale M, Bell S, Gailbraith A, McNeil K, Jones S, Khanna R. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis. 2007 Jun;9(2):165-70.</citation>
    <PMID>17462006</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>August 30, 2019</last_update_submitted>
  <last_update_submitted_qc>August 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

